EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Vonoprazan versus lansoprazole in erosive esophagitis — A systematic review and meta-analysis of randomized controlled trials

Saurabh Chandan, Smit Deliwala, Babu P Mohan, Daryl Ramai, Banreet Dhindsa, Jay Bapaye, Lena L Kassab, Ojasvini Choudhry Chandan, Antonio Facciorusso, Douglas G Adler

Indian Journal of Gastroenterology · 2023

DOI: 10.1007/s12664-023-01384-2 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Indian Journal of Gastroenterology, 2023. Verfasst von Saurabh Chandan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Creighton University School of Medicine, Omaha, NE, USA. Hauptthemen laut MEDLINE: Esophagitis, Peptic Ulcer. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Proton-pump inhibitors (PPIs) are the mainstay of treatment in erosive esophagitis (EE). An alternative to PPIs in EE is Vonoprazan, a potassium competitive acid blocker. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing vonoprazan to lansoprazole. METHODS: Multiple databases searched through November 2022. Meta-analysis was performed to assess endoscopic healing at two, four and eight weeks, including for patients with severe EE (Los Angeles C/D). Serious adverse events (SAE) leading to drug discontinuation were assessed. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. RESULTS: Four RCTs with 2208 patients were included in the final analysis. Vonoprazan 20 mg once-daily was compared to lansoprazole 30 mg once-daily dosing. Among all patients, at two and eight weeks post-treatment, vonoprazan resulted in significantly higher rates of endoscopic healing as compared to lansoprazole, risk ratios (RR) 1.1, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EsophagitisPeptic UlcerHumansLansoprazoleRandomized Controlled Trials as TopicProton Pump InhibitorsPyrrolesSulfonamides

Stichwörter der Autor:innen

Erosive esophagitisLansoprazolePPIVonoprazan

Substanzen

LansoprazoleProton Pump InhibitorsPyrroles1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineSulfonamides

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Creighton University School of Medicine, Omaha, NE, USA.
  • Division of Digestive Diseases, Emory University, Atlanta, GA, USA.
  • Gastroenterology and Hepatology, University of Utah Health School of Medicine, Salt Lake City, UT, USA.
  • Department of Gastroenterology and Hepatology, University of Nebraska Medical Center|, Omaha, NE, USA.
  • Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA.
  • Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Zitieren

APA

Chandan, S., Deliwala, S., Mohan, B. P., Ramai, D., Dhindsa, B., Bapaye, J., Kassab, L. L., Chandan, O. C., Facciorusso, A., & Adler, D. G. (2023). Vonoprazan versus lansoprazole in erosive esophagitis — A systematic review and meta-analysis of randomized controlled trials. Indian Journal of Gastroenterology. https://doi.org/10.1007/s12664-023-01384-2

Vancouver

Chandan S, Deliwala S, Mohan BP, Ramai D, Dhindsa B, Bapaye J, et al. Vonoprazan versus lansoprazole in erosive esophagitis — A systematic review and meta-analysis of randomized controlled trials. Indian Journal of Gastroenterology. 2023. doi:10.1007/s12664-023-01384-2

BibTeX
@article{Chandan2023,
  author = {Chandan, Saurabh and Deliwala, Smit and Mohan, Babu P and Ramai, Daryl and Dhindsa, Banreet and Bapaye, Jay and Kassab, Lena L and Chandan, Ojasvini Choudhry and Facciorusso, Antonio and Adler, Douglas G},
  title = {Vonoprazan versus lansoprazole in erosive esophagitis — A systematic review and meta-analysis of randomized controlled trials},
  journal = {Indian Journal of Gastroenterology},
  year = {2023},
  doi = {10.1007/s12664-023-01384-2}
}
Kostenlos starten →